To hydrolyze or not to hydrolyze: The dilemma of platelet-activating factor acetylhydrolase

Journal of Lipid Research

Volumn 55, Issue 9, 2014, Pages 1847-1854

  Marathe, Gopal Kedihitlu ^a   Pandit, Chaitanya ^b   Lakshmikanth, Chikkamenahalli Lakshminarayana ^a   Chaithra, Vyala Hanumanthareddy ^a   Jacob, Shancy Petsel ^a   D'Souza, Cletus Joseph Michael ^a  

^a UNIVERSITY OF MYSORE   (India)

^b Defence Food and Research Laboratory   (India)

Author keywords

Cardiovascular disease; Inflammation; Oxidized phospholipids; Platelet activating factor mimetics; Platelet activating factor receptor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AUTACOID; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL; ATHEROSCLEROSIS; ENZYMOLOGY; HUMAN; HYDROLYSIS; IMMUNOLOGY; PHYSIOLOGY; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ATHEROSCLEROSIS; HUMANS; HYDROLYSIS; INFLAMMATION MEDIATORS; PLATELET ACTIVATING FACTOR; RISK FACTORS;

EID: 84906875708     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R045492     Document Type: Review

References (83)

1. Prescott, S. M., and G. A. Zimmerman. 1990. Platelet-activating factor. J. Biol. Chem. 265: 17381-17384.
2. Prescott, S. M., G. A. Zimmerman, D. M. Stafforini, and T. M. McIntyre. 2000. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69: 419-445.
3. Stafforini, D. M. 2009. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc. Drugs Ther. 23: 73-83.
4. Tjoelker, L. W., and D. M. Stafforini. 2000. Platelet-activating factor acetylhydrolases in health and disease. Biochim. Biophys. Acta. 1488: 102-123.
5. Stafforini, D. M., T. M. McIntyre, M. E. Carter, and S. M. Prescott. 1987. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262: 4215-4222. (Pubitemid 17102639)
6. Tjoelker, L. W., C. Eberhardt, J. Unger, H. L. Trong, G. A. Zimmerman, T. M. McIntyre, D. M. Stafforini, S. M. Prescott, and P. W. Gray. 1995. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J. Biol. Chem. 270: 25481-25487.
7. McIntyre, T. M., S. M. Prescott, and D. M. Stafforini. 2009. The emerging roles of PAF acetylhydrolase. J. Lipid Res. 50: S255-S259.
8. Dennis, E. A. 1997. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22: 1-2. (Pubitemid 27056087)
9. Zhou, G., G. K. Marathe, B. Willard, and T. M. McIntyre. 2011. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. J. Biol. Chem. 286: 34820-34829.
10. Stafforini, D. M., J. R. Sheller, T. S. Blackwell, A. Sapirstein, F. E. Yull, T. M. McIntyre, J. V. Bonventre, S. M. Prescott, and L. J. Roberts. 2006. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J. Biol. Chem. 281: 4616-4623. (Pubitemid 43847720)
11. Marathe, G. K., S. S. Davies, K. A. Harrison, A. R. Silva, R. C. Murphy, H. Castro-Faria-Neto, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 1999. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J. Biol. Chem. 274: 28395-28404.
12. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Hörkkö, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607. (Pubitemid 27224791)
13. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, M. Febbraio, D. P. Hajjar, et al. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277: 38517-38523. (Pubitemid 35154710)
14. Yang, L., C. Latchoumycandane, M. R. McMullen, B. T. Pratt, R. Zhang, B. G. Papouchado, L. E. Nagy, A. E. Feldstein, and T. M. McIntyre. 2010. Chronic alcohol exposure increases circulating bioactive oxidized phospholipids. J. Biol. Chem. 285: 22211-22220.
15. Lehr, H. A., A. S. Weyrich, R. K. Saetzler, A. Jurek, K. E. Arfors, G. A. Zimmerman, S. M. Prescott, and T. M. McIntyre. 1997. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J. Clin. Invest. 99: 2358-2364. (Pubitemid 27227712)
16. Chen, C. H., T. Jiang, J. H. Yang, W. Jiang, J. Lu, G. K. Marathe, H. J. Pownall, C. M. Ballantyne, T. M. McIntyre, P. D. Henry, et al. 2003. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 107: 2102-2108. (Pubitemid 36532191)
17. Marathe, G. K., C. Johnson, S. D. Billings, M. D. Southall, Y. Pei, D. Spandau, R. C. Murphy, G. A. Zimmerman, T. M. McIntyre, and J. B. Travers. 2005. Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage. J. Biol. Chem. 280: 35448-35457. (Pubitemid 41532735)
18. Davies, S. S., A. V. Pontsler, G. K. Marathe, K. A. Harrison, R. C. Murphy, J. C. Hinshaw, G. D. Prestwich, A. S. Hilaire, S. M. Prescott, G. A. Zimmerman, et al. 2001. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J. Biol. Chem. 276: 16015-16023.
19. Chen, R., X. Chen, R. G. Salomon, and T. M. McIntyre. 2009. Platelet activation by low concentrations of intact oxidized LDL particles involves the PAF receptor. Arterioscler. Thromb. Vasc. Biol. 29: 363-371.
20. Marathe, G. K., G. A. Zimmerman, S. M. Prescott, and T. M. McIntyre. 2002. Activation of vascular cells by PAF-like lipids in oxidized LDL. Vascul. Pharmacol. 38: 193-200. (Pubitemid 36398265)
21. Smiley, P. L., K. E. Stremler, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 1991. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J. Biol. Chem. 266: 11104-11110. (Pubitemid 21906917)
22. Zhang, Q., N. Mousdicas, Q. Yi, M. Al-Hassani, S. D. Billings, S. M. Perkins, K. M. Howard, S. Ishii, T. Shimizu, and J. B. Travers. 2005. Staphylococcal lipoteichoic acid inhibits delayed-type hypersensitivity reactions via the platelet-activating factor receptor. J. Clin. Invest. 115: 2855-2861. (Pubitemid 41434412)
23. Lemjabbar, H., and C. Basbaum. 2002. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med. 8: 41-46. (Pubitemid 34101727)
24. Nakamura, M., Z. Honda, I. Waga, T. Matsumoto, M. Noma, and T. Shimizu. 1992. Endotoxin transduces Ca2+ signaling via platelet-activating factor receptor. FEBS Lett. 314: 125-129.
25. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
26. Choudhury, R. P., J. M. Lee, and D. R. Greaves. 2005. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat. Clin. Pract. Cardiovasc. Med. 2: 309-315. (Pubitemid 40852635)
27. Brewer, H. B., Jr. 2000. The lipid-laden foam cell: an elusive target for therapeutic intervention. J. Clin. Invest. 105: 703-705. (Pubitemid 30164106)
28. Rosenson, R. S., and D. M. Stafforini. 2012. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein- associated phospholipase A2. J. Lipid Res. 53: 1767-1782.
29. Elstad, M. R., D. M. Stafforini, T. M. McIntyre, S. M. Prescott, and G. A. Zimmerman. 1989. Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J. Biol. Chem. 264: 8467-8470. (Pubitemid 19151553)
30. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
31. Rodrigo, L., B. Mackness, P. N. Durrington, A. Hernandez, and M. I. Mackness. 2001. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354: 1-7. (Pubitemid 32183437)
32. Marathe, G. K., G. A. Zimmerman, and T. M. McIntyre. 2003. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278: 3937-3947. (Pubitemid 36801125)
33. Kriska, T., G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti. 2007. Phospholipase action of platelet-activating factor acetylhydrolase, but notparaoxonase-1, on long fatty acyl chain phospholipid hydroperoxides. J. Biol. Chem. 282: 100-108. (Pubitemid 47076629)
34. Zimmerman, G. A., S. M. Prescott, and T. M. McIntyre. 1992. Endothelial cell interactions with granulocytes: tethering and signalling molecules. Immunol. Today. 13: 93-100.
35. Alon, R., M. Aker, S. Feigelson, M. Sokolovsky-Eisenberg, D. E. Staunton, G. Cinamon, V. Grabovsky, R. Shamri, and A. Etzioni. 2003. A novel genetic leukocyte adhesion deficiency in sub second triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow. Blood. 101: 4437-4445. (Pubitemid 36857810)
36. Tjoelker, L. W., C. Wilder, C. Eberhardt, D. M. Stafforini, G. Dietsch, B. Schimpf, S. Hooper, H. Le Trong, L. S. Cousens, G. A. Zimmerman, et al. 1995. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 374: 549-553.
37. Bazan, N. G. 1995. Inflammation. A signal terminator. Nature. 374: 501-502.
38. Marathe, G. K., K. A. Harrison, R. C. Murphy, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 2000. Bioactive phospholipid oxidation products. Free Radic. Biol. Med. 28: 1762-1770. (Pubitemid 30628663)
39. Zheng, G. H., S. Q. Xiong, L. J. Mei, H. Y. Chen, T. Wang, and J. F. Chu. 2012. Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study. Inflammation. 35: 1419-1428.
40. Tsoukatos, D. C., M. Arborati, T. Liapikos, K. L. Clay, R. C. Murphy, M. J. Chapman, and E. Ninio. 1997. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF: acetylhydrolase in dense LDL. Arterioscler. Thromb. Vasc. Biol. 17: 3505-3512. (Pubitemid 28028562)
41. Vadas, P., M. Gold, B. Perelman, G. M. Liss, G. Lack, T. Blyth, F. E. Simons, K. J. Simons, D. Cass, and J. Yeung. 2008. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N. Engl. J. Med. 358: 28-35.
42. Greenberg, M. E., X. M. Li, B. G. Gugiu, X. Gu, J. Qin, R. G. Salomon, and S. L. Hazen. 2008. The lipid whisker model of the structure of oxidized cell membranes. J. Biol. Chem. 283: 2385-2396.
43. Latchoumycandane, C., G. K. Marathe, R. Zhanq, and T. M. McIntyre. 2012. Oxidatively truncated phospholipids are required agents of tumor necrosis factor α (TNFα)-induced apoptosis. J. Biol. Chem. 287: 17693-17705.
44. Matsuzawa, A., K. Hattori, J. Aoki, H. Arai, and K. Inoue. 1997. Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II. J. Biol. Chem. 272: 32315-32320. (Pubitemid 28011912)
45. Marques, M., Y. Pei, M. D. Southall, J. M. Johnston, H. Arai, J. Aoki, T. Inoue, H. Seltmann, C. C. Zouboulis, and J. B. Travers. 2002. Identification of platelet-activating factor acetylhydrolase II in human skin. J. Invest. Dermatol. 119: 913-919. (Pubitemid 35340918)
46. Huang, Y. H., L. Schäfer-Elinder, R. Wu, H. E. Claesson, and J. Frostegård. 1999. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptordependent mechanism. Clin. Exp. Immunol. 116: 326-331.
47. Nishi, E., N. Kume, H. Ochi, H. Moriwaki, S. Higashiyama, N. Taniguchi, and T. Kita. 1997. Lysophosphatidylcholine induces heparin-binding epidermal growth factor-like growth factor and interferon-gamma in human T-lymphocytes. Ann. N. Y. Acad. Sci. 811: 519-524. (Pubitemid 27308361)
48. Liu-Wu, Y., E. Hurt-Camejo, and O. Wiklund. 1998. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis. 137: 351-357. (Pubitemid 28215881)
49. Chai, Y. C., P. H. Howe, P. E. DiCorleto, and G. M. Chisolm. 1996. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J. Biol. Chem. 271: 17791-17797.
50. Jeong, Y. I., I. D. Jung, C. M. Lee, J. H. Chang, S. H. Chun, K. T. Noh, S. K. Jeong, Y. K. Shin, W. S. Lee, M. S. Kang, et al. 2009. The novel role of platelet-activating factor in protecting mice against lipopolysaccharide-induced endotoxic shock. PLoS ONE. 4: e6503-e6512.
51. Bochkov, V. N., A. Kadl, J. Huber, F. Gruber, B. R. Binder, and N. Leitinger. 2002. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature. 419: 77-81. (Pubitemid 34987873)
52. Rabini, R. A., R. Galassi, P. Fumelli, N. Dousset, M. L. Solera, P. Valdiguie, G. Curatola, G. Ferretti, M. Taus, and L. Mazzanti. 1994. Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes. 43: 915-919. (Pubitemid 24196425)
53. Chen, L., B. Liang, D. E. Froese, S. Liu, J. T. Wong, K. Tran, G. M. Hatch, D. Mymin, E. A. Kroeger, R. Y. Man, et al. 1997. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J. Lipid Res. 38: 546-553. (Pubitemid 27166697)
54. Chisolm, G. M., and Y. Chai. 2000. Regulation of cell growth by oxidized LDL. Free Radic. Biol. Med. 28: 1697-1707. (Pubitemid 30628656)
55. Marathe, G. K., A. R. Silva, H. C. Faria Neto, L. W. Tjoelker, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 2001. Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J. Lipid Res. 42: 1430-1437. (Pubitemid 34007673)
56. Ogita, T., Y. Tanaka, T. Nakaoka, R. Matsuoka, Y. Kira, M. Nakamura, T. Shimizu, and T. Fujita. 1997. Lysophosphatidylcholine transduces Ca2+ signaling via the platelet-activating factor receptor in macrophages. Am. J. Physiol. 272: H17-H24.
57. Kabarowski, J. H., K. Zhu, L. Q. Le, O. N. Witte, and Y. Xu. 2001. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science. 293: 702-705. (Pubitemid 32728673)
58. Witte, O. N., J. H. Kabarowski, Y. Xu, L. Q. Le, and K. Zhu. 2005. Retraction. Science. 307: 206.
59. Packard, C. J., D. S. O'Reilly, M. J. Caslake, A. D. McMahon, I. Ford, J. Cooney, C. H. Macphee, K. E. Suckling, M. Krishna, F. E. Wilkinson, et al. 2000. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N. Engl. J. Med. 343: 1148-1155.
60. Quarck, R., B. De Geest, D. Stengel, A. Mertens, M. Lox, G. Theilmeier, C. Michiels, M. Raes, H. Bult, D. Collen, et al. 2001. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 103: 2495-2500. (Pubitemid 32493377)
61. Henderson, W. R., Jr., J. Lu, K. M. Poole, G. N. Dietsch, and E. Y. Chi. 2000. Recombinant human platelet-activating factor acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J. Immunol. 164: 3360-3367. (Pubitemid 30149002)
62. Nagase, T., S. Ishii, H. Shindou, Y. Ouchi, and T. Shimizu. 2002. Airway hyperresponsiveness in transgenic mice overexpressing platelet activating factor receptor is mediated by an atropine-sensitive pathway. Am. J. Respir. Crit. Care Med. 165: 200-205. (Pubitemid 34084458)
63. Sato, S., K. Kume, C. Ito, S. Ishii, and T. Shimizu. 1999. Accelerated proliferation of epidermal keratinocytes by the transgenic expression of the platelet-activating factor receptor. Arch. Dermatol. Res. 291: 614-621.
64. Nagase, T., S. Ishii, K. Kume, N. Uozumi, T. Izumi, Y. Ouchi, and T. Shimizu. 1999. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J. Clin. Invest. 104: 1071-1076. (Pubitemid 29536317)
65. Ishii, S., T. Kuwaki, T. Nagase, K. Maki, F. Tashiro, S. Sunaga, W. H. Cao, K. Kume, Y. Fukuchi, K. Ikuta, et al. 1998. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. 187: 1779-1788. (Pubitemid 28262442)
66. Serruys, P. W., H. M. García-García, P. Buszman, P. Erne, S. Verheye, M. Aschermann, H. Duckers, O. Bleie, D. Dudek, H. E. Bøtker, et al. 2008. Effects of the direct lipoprotein-associated phospholipase A 2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 118: 1172-1182.
67. Yost, C. C., A. S. Weyrich, and G. A. Zimmerman. 2010. The platelet activating factor (PAF) signalling cascade in systemic inflammatory responses. Biochimie. 92: 692-697.
68. Lu, J., M. Pierce, A. Franklin, T. Jilling, D. M. Stafforini, and M. Caplan. 2010. Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis. Pediatr. Res. 68: 225-230.
69. Stafforini, D. M., K. Satoh, D. L. Atkinson, L. W. Tjoelker, C. Eberhardt, H. Yoshida, T. Imaizumi, S. Takamatsu, G. A. Zimmerman, T. M. McIntyre, et al. 1996. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J. Clin. Invest. 97: 2784-2791. (Pubitemid 26197091)
70. Opal, S., P. F. Laterre, E. Abraham, B. Francois, X. Wittebole, S. Lowry, J. F. Dhainaut, B. Warren, T. Dugernier, A. Lopez, et al. 2004. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial. Crit. Care Med. 32: 332-341. (Pubitemid 38234108)
71. Williams, S. C. P. 2012. After Xigris, researchers look to new targets to combat sepsis. Nat. Med. 18: 1001.
72. Minneci, P. C., K. J. Deans, S. M. Banks, P. Q. Eichacker, and C. Natanson. 2004. Should we continue to target the platelet-activating factor pathway in septic patients? Crit. Care Med. 32: 585-588. (Pubitemid 38234146)
73. Camerer, E., J. B. Regard, I. Cornelissen, Y. Srinivasan, D. N. Duong, D. Palmer, T. H. Pham, J. S. Wong, R. Pappu, and S. R. Coughlin. 2009. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J. Clin. Invest. 119: 1871-1879.
74. Korhonen, H., B. Fisslthaler, A. Moers, A. Wirth, D. Habermehl, T. Wieland, G. Schutz, N. Wettschureck, I. Fleming, and S. Offermanns. 2009. Anaphylactic shock depends on endothelial Gq/G11. J. Exp. Med. 206: 411-420.
75. MacRitchie, A. N., A. A. Gardner, S. M. Prescott, and D. M. Stafforini. 2007. Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation. FASEB J. 21: 1164-1176. (Pubitemid 46495706)
76. Gardner, A. A., E. C. Reichert, T. S. Alexander, M. K. Topham, and D. M. Stafforini. 2010. Novel mechanism for regulation of plasma platelet-activating factor acetylhydrolase expression in mammalian cells. Biochem. J. 428: 269-279.
77. Cao, Y., D. M. Stafforini, G. A. Zimmerman, T. M. McIntyre, and S. M. Prescott. 1998. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J. Biol. Chem. 273: 4012-4020. (Pubitemid 28103265)
78. Chen, C-H. 2004. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr. Opin. Lipidol. 15: 337-341. (Pubitemid 38716568)
79. Karabina, S. A., and E. Ninio. 2006. Plasma PAF-acetylhydrolase: an unfulfilled promise? Biochim. Biophys. Acta. 1761: 1351-1358. (Pubitemid 44738700)
80. Whatley, R. E., K. L. Clay, F. H. Chilton, M. Triggiani, G. A. Zimmerman, T. M. McIntyre, and S. M. Prescott. 1992. Relative amounts of 1-O-alkyl- and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in stimulated endothelial cells. Prostaglandins. 43: 21-29.
81. McIntyre, T. M., G. A. Zimmerman, K. Satoh, and S. M. Prescott. 1985. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J. Clin. Invest. 76: 271-280. (Pubitemid 15240447)
82. Chen, J., L. Yang, J. M. Foulks, A. S. Weyrich, G. K. Marathe, and T. M. McIntyre. 2007. Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis. J. Lipid Res. 48: 2365-2376. (Pubitemid 350058748)
83. Shindou, H., D. Hishikawa, H. Nakanishi, T. Harayama, S. Ishii, R. Taguchi, and T. Shimizu. 2007. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA: LYSO-PAF acetyltransferase. J. Biol. Chem. 282: 6532-6539. (Pubitemid 47100867)